Seeking Alpha

The FDA has approved Novartis' (NVS) Signifor drug to treat sufferers of Cushing's disease who...

The FDA has approved Novartis' (NVS) Signifor drug to treat sufferers of Cushing's disease who aren't eligible for surgery. Cushing's disease is a rare hormone condition that can cause obesity, skin that bruises easily and excess hair growth. Novartis will have to carry three more analyses of Signifor for high sugar levels in patients' blood, the risks stemming from such levels, and for monitoring the long-term use of the treatment.
From other sites
Comments (1)
  • Reveszla
    , contributor
    Comment (1) | Send Message
     
    Signifor is a novel cyclohexapeptidic analogue of Somatostatin and binds with high affinity to the sst5 receptor, resulting in the inhibition ACTH-release (ACTH=adrenocorticotro... hormone). Since Cushing's disease is due to overproduction of ACTH, Signifor is the drug of choice for its treatment. First generation Somatostatin analogues like Octreotide and Lanreotide had a 40-500 fold lower affinity to the sst5 receptor and hence are less effective.
    17 Dec 2012, 05:43 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs